A Randomized Controlled Trial of Vitamin D Supplementation on Preventing Postmenopausal Bone Loss and Modifying Bone Metabolism Using Identical Twin Pairs
Open Access
- 1 November 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 15 (11) , 2276-2283
Abstract
Vitamin D supplementation, when given with calcium, has been shown to increase bone mineral density (BMD) and reduce the incidence of hip fracture in elderly subjects. Despite its widespread use, the benefits of vitamin D supplementation in younger women and as a single agent are less clear. We performed a randomized co‐twin, placebo‐controlled, double‐blind trial over 2 years to measure the effect of vitamin D3 supplementation on bone density and bone metabolism in young postmenopausal women. Seventy‐nine monozygotic (MZ) twin pairs (mean age, 58.7 years; range, 47–70 years) were recruited. For each twin pair, one was randomized to 800 IU cholecalciferol/day for 2 years and the other was randomized to placebo. BMD was measured at the spine and hip and heel ultrasound at baseline, 12, 18, and 24 months. Samples were collected at 0, 3, and 6 months to measure serum calcium, 25‐hydroxyvitamin D [25(OH)D], parathyroid hormone (PTH), osteocalcin, and urinary deoxypyridinoline (DPD). In total, 64 pairs completed the study. No differences in baseline characteristics were seen between the groups. At 6 months, the treatment group had an increase in serum vitamin D [mean ± SEM intrapair difference, 14.1 ± 2.4 μg/liter (p < 0.001)]. There were no significant differences in other serum measurements or bone markers at 3 months or 6 months. At 24 months, no significant treatment effect was seen on BMD or calcaneal ultrasound change within pairs. Subanalysis of treatment response by vitamin D receptor (VDR) genotype revealed no significant difference in effect on BMD variables with treatment. On the basis of these results, vitamin D supplementation, on its own, cannot be recommended routinely as an osteoporosis prevention for healthy postmenopausal women with normal vitamin D levels under the age of 70 years.Keywords
This publication has 42 references indexed in Scilit:
- Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysisJournal of Bone and Mineral Research, 1996
- Bone mineral density and bone markers in relation to vitamin D receptor gene polymorphisms in chinese men and womenBone, 1996
- Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women: The OFELY studyJournal of Bone and Mineral Research, 1996
- The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: A study of postmenopausal twinsJournal of Bone and Mineral Research, 1996
- The relationship between osteoarthritis and osteoporosis in the general population: the Chingford Study.Annals of the Rheumatic Diseases, 1994
- Bone density parathyroid hormone and 25-hydroxyvitamin D concentrations in middle aged women.BMJ, 1992
- Treatment of Postmenopausal Osteoporosis with Calcitriol or CalciumNew England Journal of Medicine, 1992
- Clinical Use of Bone DensitometryNew England Journal of Medicine, 1991
- Effect of Vitamin D Intake on Seasonal Variations in Parathyroid Hormone Secretion in Postmenopausal WomenNew England Journal of Medicine, 1989
- Aging decreases the capacity of human skin to produce vitamin D3.Journal of Clinical Investigation, 1985